A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer
Immune checkpoint inhibitors such as Nivolumab work by preventing the inactivation of host T-cells by tumour cells, thereby allowing the T-cells to attack the tumour cells, which results in tumour tissue necrosis. We describe a 78-year-old woman with metastatic lung adenocarcinoma treated with Nivol...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2019/8356148 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553704550563840 |
|---|---|
| author | Suyanto Suyanto Daniel Yeo Sarah Khan |
| author_facet | Suyanto Suyanto Daniel Yeo Sarah Khan |
| author_sort | Suyanto Suyanto |
| collection | DOAJ |
| description | Immune checkpoint inhibitors such as Nivolumab work by preventing the inactivation of host T-cells by tumour cells, thereby allowing the T-cells to attack the tumour cells, which results in tumour tissue necrosis. We describe a 78-year-old woman with metastatic lung adenocarcinoma treated with Nivolumab after disease progression following first-line chemotherapy. Computed tomography (CT) after 3 cycles showed a smaller left lower lobe (LLL) primary and stable right lower lobe (RLL) metastatic lesion. CT after 9 cycles showed a reduced RLL mass and an increase in LLL primary. However, CT after 15 cycles showed that the RLL mass had further reduced in size but the LLL mass was significantly larger. The biopsy of the LLL lesion showed necrotic areas and reactive inflammatory changes, without residual malignancy. A repeat CT after further 4 cycles confirmed tumour regression in both the primary and the metastatic lesions. There was a prior reported case of pseudoprogression in a non-small-cell lung cancer patient who had 7 cycles of Nivolumab, and it was diagnosed during a further line of chemotherapy. Here, we report a patient with pseudoprogression during treatment with Nivolumab and at a much later time, after 15 cycles. |
| format | Article |
| id | doaj-art-b26b19d8a4df411d8ae786272d7e0946 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-b26b19d8a4df411d8ae786272d7e09462025-02-03T05:53:31ZengWileyCase Reports in Oncological Medicine2090-67062090-67142019-01-01201910.1155/2019/83561488356148A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung CancerSuyanto Suyanto0Daniel Yeo1Sarah Khan2Nottingham University Hospital NHS Trust, UKNottingham University Hospital NHS Trust, UKNottingham University Hospital NHS Trust, UKImmune checkpoint inhibitors such as Nivolumab work by preventing the inactivation of host T-cells by tumour cells, thereby allowing the T-cells to attack the tumour cells, which results in tumour tissue necrosis. We describe a 78-year-old woman with metastatic lung adenocarcinoma treated with Nivolumab after disease progression following first-line chemotherapy. Computed tomography (CT) after 3 cycles showed a smaller left lower lobe (LLL) primary and stable right lower lobe (RLL) metastatic lesion. CT after 9 cycles showed a reduced RLL mass and an increase in LLL primary. However, CT after 15 cycles showed that the RLL mass had further reduced in size but the LLL mass was significantly larger. The biopsy of the LLL lesion showed necrotic areas and reactive inflammatory changes, without residual malignancy. A repeat CT after further 4 cycles confirmed tumour regression in both the primary and the metastatic lesions. There was a prior reported case of pseudoprogression in a non-small-cell lung cancer patient who had 7 cycles of Nivolumab, and it was diagnosed during a further line of chemotherapy. Here, we report a patient with pseudoprogression during treatment with Nivolumab and at a much later time, after 15 cycles.http://dx.doi.org/10.1155/2019/8356148 |
| spellingShingle | Suyanto Suyanto Daniel Yeo Sarah Khan A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer Case Reports in Oncological Medicine |
| title | A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer |
| title_full | A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer |
| title_fullStr | A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer |
| title_full_unstemmed | A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer |
| title_short | A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer |
| title_sort | rare delayed atypical pseudoprogression in nivolumab treated non small cell lung cancer |
| url | http://dx.doi.org/10.1155/2019/8356148 |
| work_keys_str_mv | AT suyantosuyanto araredelayedatypicalpseudoprogressioninnivolumabtreatednonsmallcelllungcancer AT danielyeo araredelayedatypicalpseudoprogressioninnivolumabtreatednonsmallcelllungcancer AT sarahkhan araredelayedatypicalpseudoprogressioninnivolumabtreatednonsmallcelllungcancer AT suyantosuyanto raredelayedatypicalpseudoprogressioninnivolumabtreatednonsmallcelllungcancer AT danielyeo raredelayedatypicalpseudoprogressioninnivolumabtreatednonsmallcelllungcancer AT sarahkhan raredelayedatypicalpseudoprogressioninnivolumabtreatednonsmallcelllungcancer |